Cwm LLC Raises Position in Tempus AI, Inc. $TEM

Key Points

• Cwm LLC increased its stake in Tempus AI, Inc. by 18.1% in the second quarter, owning a total of 183,729 shares valued at approximately $11.67 million.
• Tempus AI's shares opened at $94.47 with a market capitalization of $16.41 billion, showing a significant increase in revenue of 89.5% year-over-year despite a negative net margin.
• Insider transactions revealed that executives sold shares at an average price of $74.65, reducing their positions while insiders currently hold 26.27% of the company's stock.

Cwm LLC boosted its stake in Tempus AI, Inc. (NASDAQ:TEM - Free Report) by 18.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 183,729 shares of the company's stock after buying an additional 28,193 shares during the period. Cwm LLC owned 0.11% of Tempus AI worth $11,674,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. First Horizon Advisors Inc. lifted its holdings in Tempus AI by 12.7% in the first quarter. First Horizon Advisors Inc. now owns 1,849 shares of the company's stock worth $89,000 after buying an additional 208 shares during the period. Farther Finance Advisors LLC boosted its position in shares of Tempus AI by 59.9% in the 2nd quarter. Farther Finance Advisors LLC now owns 884 shares of the company's stock worth $56,000 after purchasing an additional 331 shares in the last quarter. Bartlett & CO. Wealth Management LLC boosted its position in shares of Tempus AI by 100.0% in the 1st quarter. Bartlett & CO. Wealth Management LLC now owns 800 shares of the company's stock worth $39,000 after purchasing an additional 400 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Tempus AI by 10.1% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,594 shares of the company's stock worth $268,000 after purchasing an additional 515 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its position in shares of Tempus AI by 6.1% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 9,681 shares of the company's stock worth $590,000 after purchasing an additional 560 shares in the last quarter. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

Tempus AI Price Performance

Shares of TEM opened at $94.47 on Tuesday. The company has a market capitalization of $16.41 billion, a P/E ratio of -79.39 and a beta of 4.87. The company has a quick ratio of 1.43, a current ratio of 1.54 and a debt-to-equity ratio of 2.58. The firm has a 50 day moving average of $79.63 and a 200 day moving average of $65.19. Tempus AI, Inc. has a twelve month low of $31.36 and a twelve month high of $104.32.

Tempus AI (NASDAQ:TEM - Get Free Report) last announced its quarterly earnings results on Friday, August 8th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.01. The company had revenue of $314.64 million during the quarter, compared to the consensus estimate of $296.84 million. Tempus AI had a negative net margin of 20.98% and a negative return on equity of 122.86%. The firm's quarterly revenue was up 89.5% compared to the same quarter last year. During the same quarter last year, the firm earned ($6.86) earnings per share. Tempus AI has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that Tempus AI, Inc. will post -6.15 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Tempus AI news, EVP Erik Phelps sold 3,664 shares of Tempus AI stock in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $74.65, for a total value of $273,517.60. Following the completion of the sale, the executive vice president owned 94,115 shares of the company's stock, valued at approximately $7,025,684.75. The trade was a 3.75% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO James William Rogers sold 7,528 shares of Tempus AI stock in a transaction that occurred on Tuesday, August 19th. The stock was sold at an average price of $74.65, for a total transaction of $561,965.20. Following the completion of the sale, the chief financial officer directly owned 138,473 shares of the company's stock, valued at approximately $10,337,009.45. This trade represents a 5.16% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 933,662 shares of company stock worth $68,070,993 in the last 90 days. Insiders own 26.27% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on TEM shares. Bank of America boosted their price target on Tempus AI from $68.00 to $70.00 and gave the stock a "neutral" rating in a research report on Wednesday, June 25th. Needham & Company LLC reissued a "buy" rating and issued a $70.00 price target on shares of Tempus AI in a research report on Friday, August 8th. BTIG Research boosted their price target on Tempus AI from $75.00 to $85.00 and gave the stock a "buy" rating in a research report on Wednesday, August 20th. Guggenheim boosted their price target on Tempus AI from $80.00 to $95.00 and gave the stock a "buy" rating in a research report on Friday, September 26th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Tempus AI in a research report on Wednesday, October 8th. Seven analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Tempus AI has a consensus rating of "Hold" and a consensus price target of $71.83.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

Want to see what other hedge funds are holding TEM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tempus AI, Inc. (NASDAQ:TEM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.